- Home
- MSN vs TOVX Comparison
MSN vs TOVX Comparison
Compare MSN & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSN | TOVX |
|---|---|---|
| Founded | 1948 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 6.4M |
| IPO Year | 1995 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MSN | TOVX |
|---|---|---|
| Price | $0.38 | $0.21 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.9K | ★ 2.6M |
| Earning Date | 02-17-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $77,829,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.32 | $0.16 |
| 52 Week High | $0.85 | $1.50 |
Technical Indicators
Market Signals| Indicator | MSN | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 62.42 |
| Support Level | $0.36 | $0.17 |
| Resistance Level | $0.42 | $0.22 |
| Average True Range (ATR) | 0.03 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 69.91 | 42.55 |
Price Performance
Historical ComparisonAbout MSN Emerson Radio Corporation
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.